Efficacy and toxicity of belotecan for relapsed or refractory small cell lung cancer patients

Journal of Thoracic Oncology

Volumn 7, Issue 4, 2012, Pages 731-736

  Kim, Gun Min ^a,b   Kim, Young Sam ^b   Ae Kang, Young ^b   Jeong, Jae Heon ^c   Kim, Sun Mi ^b   Hong, Yun Kyoung ^d   Sung, Ji Hee ^d   Lim, Seung Taek ^b   Kim, Joo Hang ^a,b   Kim, Se Kyu ^b   Cho, Byoung Chul ^a,b  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c Kyung Hee University Hospital   (South Korea)

^d JE UK Institute for Cancer Research   (South Korea)

Author keywords

Belotecan; Refractory; Relapsed; Small cell lung cancer

Indexed keywords

BELOTECAN;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; BLEEDING; CANCER RELAPSE; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DYSPNEA; FEMALE; HUMAN; INFECTION; LUNG SMALL CELL CANCER; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL RESPONSE RATE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

EID: 84863344528     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31824b23cb     Document Type: Article

References (20)

1. Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006;24:4539-4544. (Pubitemid 46630948)
2. Kim YH, Mishima M. Second-line chemotherapy for small-cell lung cancer (SCLC). Cancer Treat Rev 2011;37:143-150.
3. Jackman DM, Johnson BE. Small-cell lung cancer. Lancet 2005;366:1385-1396. (Pubitemid 41443406)
4. Ardizzoni A, Hansen H, Dombernowsky P, et al. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. J Clin Oncol 1997;15:2090-2096.
5. OBrien ME, Ciuleanu TE, Tsekov H, et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 2006;24:5441-5447. (Pubitemid 46623178)
6. Park SH, Cho EK, Kim Y, et al. Salvage treatment with topotecan in patients with irinotecan-refractory small cell lung cancer. Cancer Chemother Pharmacol 2008;62:1009-1014.
7. Eckardt JR, von Pawel J, Pujol JL, et al. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol 2007;25:2086-2092. (Pubitemid 46972795)
8. von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999;17:658-667. (Pubitemid 29075255)
9. Ettinger DS, Jotte R, Lorigan P, et al. Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer. J Clin Oncol 2010;28:2598-2603.
10. Kaira K, Sunaga N, Tomizawa Y, et al. A phase II study of amrubicin, a synthetic 9-aminoanthracycline, in patients with previously treated lung cancer. Lung Cancer 2010;69:99-104.
11. Onoda S, Masuda N, Seto T, et al. Thoracic Oncology Research Group Study 0301. Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301. J Clin Oncol 2006;24:5448-5453. (Pubitemid 46623179)
12. Inoue A, Sugawara S, Yamazaki K, et al. Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402. J Clin Oncol 2008;26:5401-5406.
13. Crul M. CKD-602. Chong Kun Dang. Curr Opin Investig Drugs 2003;4:1455-1459.
14. Lee DH, Kim SW, Suh C, et al. Belotecan, new camptothecin analogue, is active in patients with small-cell lung cancer: results of a multicenter early phase II study. Ann Oncol 2008;19:123-127.
15. Lee DH, Kim SW, Suh C, et al. Multicenter phase 2 study of belotecan, a new camptothecin analog, and cisplatin for chemotherapy-naive patients with extensive-disease small cell lung cancer. Cancer 2010;116:132-136.
16. Kim SJ, Kim JS, Kim SC, et al. A multicenter phase II study of belotecan, new camptothecin analogue, in patients with previously untreated extensive stage disease small cell lung cancer. Lung Cancer 2010;68:446-449.
17. Hong J, Jung M, Kim YJ, et al. Phase II study of combined belotecan and cisplatin as first-line chemotherapy in patients with extensive disease of small cell lung cancer. Cancer Chemother Pharmacol 2012;69:215-220.
18. Jeong J, Cho BC, Sohn JH, et al. Belotecan for relapsing small-cell lung cancer patients initially treated with an irinotecan-containing chemotherapy: a phase II trial. Lung Cancer 2010;70:77-81.
19. Rhee CK, Lee SH, Kim JS, et al. A multicenter phase II study of belotecan, a new camptothecin analogue, as a second-line therapy in patients with small cell lung cancer. Lung Cancer 2011;72:64-67.
20. von Pawel J, Jotte R, Spigel DR, et al. Randomized phase III trial of amrubicin versus topotecan (Topo) as second-line treatment for small cell lung cancer (SCLC). Proceedings of the Annual Meeting of the American Society of Clinical Oncology 2011. J Clin Oncol 2011;29:(Suppl; abstr 7000).